ArticleJournal of computer-aided molecular design2026
Jervine-induced suppression of triple-negative breast cancer (TNBC) cells growth through the regulation of Wnt signaling pathway- an in-silico and in-vitro approach.
Article in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Kabbe condensation: a comprehensive review of spirochromanone synthesis and medicinal applications.RSC advances · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC), the most aggressive cancer in women, continues to exhibit serious health concerns globally. However, the existing limitations in current therapeutics demand novel, broad-spectrum and cost-effective treatment. Herbal medicines are currently used as effective anticancer treatments, comprising specific plant-derived bioactive compounds. Jervine, a steroidal alkaloid, has proven to have anticancer activities; hence, its therapeutic mechanism in contributing to BC tumorigenesis remains incompletely elucidated.
objectiveThis study investigates the molecular mechanism of action of jervine’s anticancer efficacy against BC via in silico and in vitro analyses.
methodsIn silico analysis, including network pharmacology, pharmacokinetics, molecular docking, and molecular dynamics simulations, was performed to explore jervine’s therapeutic potential against BC targets. Further,an invitro analysis was evaluated for its cytotoxic effects using MDA-MB-231 triple-negative breast cancer (TNBC) cells, using the MTT assay, followed by gene expression analysis via RT-PCR.
resultsThe combined findings from network pharmacology, molecular docking, and molecular simulation analyses clearly demonstrated that jervine possesses favourable drug-like properties and forms stable interactions with multiple Wnt signalling targets (WNT5A, FZD5, LRP6), as well as key modulators from other pathways, including BMP4 (a member of the TGF-β family) and SHH (a central component of Hedgehog signalling), all of which are associated with breast cancer. In vitro analysis of MDA-MB-231 cells using the MTT assay showed that jervine exhibited significant cytotoxic effects, with IC50 values of 18.55 μM at 24 h and 13.23 μM at 48 h. Further, gene expression analysis particularly emphasized that jervine significantly controlled the dysregulated WNT signalling targeted genes (Wnt 5a, DVL2, FZD5, LRP6) and including SHH, BMP4 genes mRNA expression levels and thereby inhibited the proliferation of BC cells. Further, these in vitro results coincide with the findings of the computational studies.
Indexed as
Identifiers
41639332What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.